The new report* states that the recent economic recession in Europe had minimal impact on Morocco, whose economic situation is relatively stable. However, poverty remains a critical issue in Morocco despite the decreasing trend shown by the country’s poverty rate. This has spurred the government to introduce the National Initiative for Human Development (Initiative Nationale pour le Développement Humain, INDH), a program aimed at poverty alleviation.
This financial uncertainty directly affects the Moroccan healthcare system, as private sector expenditure is high in the country. The limited availability of medicines in public hospitals pushes many citizens to resort to private healthcare, which they must fund themselves.
In 2011, the Moroccan elderly made up 6.1% of the total population, and is expected to increase to a
7.5% share by 2020. This represents significant demand for the care of degenerative and chronic conditions, which are more commonly suffered in old age.
For Sample Pages, please click or add the below link to your browser:
The Moroccan government regulates the healthcare system under the Ministry of Health (Ministère de la santé, MoH), with insurance coverage schemes working to support financially vulnerable people. For instance, the Mandatory Health Insurance (l’Assurance Maladie Obligatoire, AMO) is the basic healthcare coverage for civil servants and private sector employees in Morocco, while the Medical Assistance Program (Regime d’Assistance Medicale, RAMED) provides for economically disadvantaged people. These vital healthcare reforms were introduced by the MoH to provide access to healthcare services for the people of Turkey, yet private medical care is still a booming trade.
The pharmaceutical market in Morocco was valued at approximately US$0.6 billion in 2006, and is projected to reach US$2.9 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 11.1% (US– Morocco Free Trade Agreement, FTA, 2007).
This report identifies the key trends in the Morocco healthcare market, as well as providing insights on the demographic, regulatory, and reimbursement landscape, and the healthcare infrastructure of Morocco. Most importantly, it provides valuable insights on the trends and segmentation of the pharmaceutical market.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For further details, please click or add the below link to your browser:
Visit our report store:
For more details contact:pressreleases@
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782